KEYNOTE-021 G队列长期总生存结果:帕博利珠单抗联合培美曲塞卡铂一线治疗晚期非鳞NSCLC
KEYNOTE-021 G队列纳入无EGFR/ALK突变的晚期非鳞NSCLC患者,随机接受帕博利珠单抗联合培美曲塞卡铂或单纯化疗。中位随访49.4个月,联合组客观缓解率和无进展生存期持续优于化疗组,中位总生存期分别为34.5个月和21.1个月,化疗组70%交叉至抗PD-(L)1治疗。完成2年帕博利珠单抗治疗的患者92%存活,3年缓解持续时间估计为100%。
要点
- 联合组中位无进展生存期24.5个月,化疗组9.9个月,HR 0.54(95%CI 0.35-0.83)。
- 联合组中位总生存期34.5个月,化疗组21.1个月,HR 0.71(95%CI 0.45-1.12)。
- 完成2年帕博利珠单抗治疗的12例患者中92%存活,3年缓解持续时间估计为100%。
核心结论
- 一线帕博利珠单抗联合培美曲塞卡铂较单纯化疗在晚期非鳞NSCLC中持续显示缓解和生存获益,完成2年治疗者临床获益持久。
研究设计与样本
- KEYNOTE-021 G队列为开放标签随机1:1研究,纳入既往未治疗、无EGFR/ALK敏感突变的晚期非鳞NSCLC患者。
- 联合组接受帕博利珠单抗200 mg联合培美曲塞500 mg/m2及卡铂AUC 5 mg/mL/min四周期,每3周给药,帕博利珠单抗最长2年,可选培美曲塞维持。
- 化疗组疾病进展后可交叉至帕博利珠单抗单药治疗。
- 联合组60例,化疗组63例。
主要发现
- 从随机化至数据截止中位时间49.4个月,联合组客观缓解率58%,化疗组33%。
- 联合组中位无进展生存期24.5个月,化疗组9.9个月,HR 0.54(95%CI 0.35-0.83), regardless of PD-L1 status。
- 联合组中位总生存期34.5个月,化疗组21.1个月,HR 0.71(95%CI 0.45-1.12),化疗组交叉率为70%。
- 完成2年帕博利珠单抗治疗的12例患者中,数据截止时92%存活,3年缓解持续时间估计为100%。
- 联合组3-5级治疗相关不良事件发生率39%,化疗组31%。
关键数值与推荐
- 客观缓解率:联合组58% vs 化疗组33%。
- 中位无进展生存期:联合组24.5个月 vs 化疗组9.9个月,HR 0.54(95%CI 0.35-0.83)。
- 中位总生存期:联合组34.5个月 vs 化疗组21.1个月,HR 0.71(95%CI 0.45-1.12)。
- 完成2年帕博利珠单抗治疗者92%存活,3年缓解持续时间估计100%。
- 3-5级治疗相关不良事件:联合组39%,化疗组31%。
临床怎么用
- 对于无EGFR/ALK敏感突变的晚期非鳞NSCLC,一线可考虑帕博利珠单抗联合培美曲塞卡铂。
- 联合方案获益不受PD-L1状态影响,长期随访未观察到新安全性信号。
- 完成2年帕博利珠单抗治疗的患者可获得持久临床获益。
局限性
- 总生存期HR的95%CI上限超过1,差异未达统计学显著。
- 化疗组70%交叉至抗PD-(L)1治疗可能影响总生存期比较。
- 完成2年帕博利珠单抗治疗的患者仅12例,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In cohort G of KEYNOTE-021 (NCT02039674), first-line pembrolizumab plus pemetrexed-carboplatin significantly improved the objective response rate and progression-free survival versus chemotherapy alone with manageable toxicity in advanced nonsquamous NSCLC. We report the long-term outcomes from this study. METHODS: Patients with previously untreated advanced nonsquamous NSCLC without sensitizing EGFR or ALK alterations were randomly assigned 1:1 to receive open-label pemetrexed 500 mg/m2 plus carboplatin at area under the concentration-time curve of 5 mg/mL/min (four cycles) with or without pembrolizumab 200 mg (up to 2 years), with optional pemetrexed maintenance, each administered every 3 weeks. Eligible patients could crossover from the chemotherapy arm to pembrolizumab monotherapy after progression. Responses were assessed per the Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: After the median time of 49.4 months from randomization to data cutoff, objective response rate (58% versus 33%) and progression-free survival (median: 24.5 versus 9.9 mo; hazard ratio: 0.54; 95% confidence interval: 0.35‒0.83) remained improved with pembrolizumab combination (n = 60) versus chemotherapy (n = 63), regardless of programmed death ligand 1 status. Median overall survival was 34.5 versus 21.1 months (hazard ratio: 0.71; 95% confidence interval: 0.45‒1.12), despite a 70% crossover rate from chemotherapy alone to anti‒programmed death (ligand) 1 therapy. Among the 12 patients who completed 2 years of pembrolizumab, 92% were alive at data cutoff; the estimated 3-year duration of response rate was 100%. Grade 3 to 5 treatment-related adverse events occurred in 39% of patients receiving pembrolizumab combination and 31% receiving chemotherapy. CONCLUSIONS: First-line pembrolizumab plus pemetrexed-carboplatin continued to show improved response and survival versus chemotherapy alone in advanced nonsquamous NSCLC, with durable clinical benefit in patients who completed 2 years of therapy. No new safety signals were observed with longer follow-up.
引用
- Awad MM, Gadgeel SM, Borghaei H, et al. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2020. PMID: 33069888. doi:10.1016/j.jtho.2020.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。